Clusterin Expression in Colorectal Carcinomas

Teresa Téllez; Desirée Martin-García; Maximino Redondo; Marilina García-Aranda

doi:10.3390/ijms241914641

Clusterin Expression in Colorectal Carcinomas

Int J Mol Sci. 2023 Sep 27;24(19):14641. doi: 10.3390/ijms241914641.

Authors

Teresa Téllez^{1

2

3}, Desirée Martin-García^{1

2

3

4}, Maximino Redondo^{1

2

3

4}, Marilina García-Aranda^{2

3

4}

Affiliations

¹ Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Malaga, Spain.
² Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29590 Malaga, Spain.
³ Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Malaga, Spain.
⁴ Research and Innovation Unit, Hospital Costa del Sol, 29602 Marbella, Spain.

Abstract

Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. In terms of overall mortality, it ranks second due to, among other factors, problems with screening programs, which means that one of the factors that directly impacts survival and treatment success is early detection of the disease. Clusterin (CLU) is a molecular chaperone that has been linked to tumorigenesis, cancer progression and resistance to anticancer treatments, which has made it a promising drug target. However, it is still necessary to continue this line of research and to adjust the situations in which its use is more favorable. The aim of this paper is to review the current genetic knowledge on the role of CLU in tumorigenesis and cancer progression in general, and discuss its possible use as a therapeutic target in colorectal cancer.

Keywords: biomarker; clusterin; colorectal cancer; personalized medicine; targeted treatment; tumorigenesis.

Publication types

Review

MeSH terms

Carcinogenesis
Clusterin / genetics
Clusterin / metabolism
Colorectal Neoplasms* / genetics
Humans
Lung Neoplasms* / pathology

Substances

Clusterin

Grants and funding

The researcher Marilina García-Aranda is the benefactor of a postdoctoral contract financed by the European Social Fund—Operational Program of Andalusia 2014–2020 for the “Incorporation of Research Personnel with a PhD degree in the field of Health Sciences and Technologies in R&D and Innovation Centers of the Public Health System of Andalusia” (RH-0055-2020). This work was partially supported by grants from the University of Malaga—Consejería de Transformación Económica, Industria, Conocimiento y Universidades—Junta de Andalucia (UMA20-FEDERJA-161) and from Instituto de Salud Carlos III (PI18/01181, PI21/00252) and were cofunded by the European Regional Development fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.